Cargando…
Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 Update
Type 2 diabetes is characterised by chronic hyperglycaemia and variable degrees of insulin deficiency and resistance. Hyperglycaemia and elevated fatty acids exert harmful effects on β-cell function, regeneration and apoptosis (gluco-lipotoxicity). Furthermore, chronic hyperglycaemia triggers a vici...
Autores principales: | Hanefeld, Markolf, Fleischmann, Holger, Siegmund, Thorsten, Seufert, Jochen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376805/ https://www.ncbi.nlm.nih.gov/pubmed/32564335 http://dx.doi.org/10.1007/s13300-020-00855-5 |
Ejemplares similares
-
Insulin Use Early in the Course of Type 2 Diabetes Mellitus: The ORIGIN Trial
por: Hanefeld, Markolf, et al.
Publicado: (2013) -
Effectiveness and Safety of Switching Rapid-Acting Insulins to Insulin Glulisine in Patients with Diabetes: The Observational IGLU-S Study
por: Seufert, Jochen, et al.
Publicado: (2021) -
Effectiveness and tolerability of treatment intensification to basal–bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational study
por: Pfohl, Martin, et al.
Publicado: (2015) -
Effectiveness and Safety of Insulin Glulisine When Initiating Supplementary Prandial Insulin Treatment (SIT) in Insulin-Naïve Patients with Type 2 Diabetes: The Observational IGLU-SIT Study
por: Pfohl, Martin, et al.
Publicado: (2021) -
Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes
por: Hanefeld, Markolf
Publicado: (2007)